48 results
8-K
EX-1.1
NRBO
NeuroBo Pharmaceuticals Inc
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm
Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship
424B4
NRBO
NeuroBo Pharmaceuticals Inc
7 Nov 22
Prospectus supplement with pricing info
9:07am
application, or MAA, in the European Union from the European Medicines Agency, or EMA.
Successfully completing clinical trials and obtaining approval … developing and commercializing niclosamide for the treatment of COVID-19 symptoms, including Daewoong, Union Therapeutics, TFF and FirstWave. Approved
8-K
EX-10.1
u9ca7t6jhfkh98h4z
14 Sep 22
Entry into a Material Definitive Agreement
5:11pm
8-K
EX-10.3
aajy 6hvexu3
14 Sep 22
Entry into a Material Definitive Agreement
5:11pm
8-K
EX-10.1
rfmuzb743el6zi5
4 Oct 21
Neurobo Pharmaceuticals Announces $14 Million Registered Direct Offering
4:46pm
8-K
EX-99.1
agky vg355j0b7v7
5 Mar 21
Company Presentation Confidential March 2021
8:41am
8-K
EX-10.1
tm6yyyw2b
21 Jan 21
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
5:03pm
8-K
EX-2.1
jaqa9n38iu77i g2kt
6 Jan 21
NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program
4:05pm